Table 2—

Effects of fenofibrate in 24 patients with metabolic syndrome among 46 hypertryglyceridemic patients

VariablesPlaceboFenofibratePercent changes
Age (years)58 ± 2 (42–74)
Sex (men:women)10:14
BMI (kg/m2)25.92 ± 0.58 (2.84)25.90 ± 0.57 (2.82)
Lipids (mg/dl)
    Total cholesterol219 ± 8 (42)205 ± 7 (35)−5 ± 3 (16)
    Triglycerides316 ± 18 (90)147 ± 13 (59)*−51 ± 5 (24)*
    LDL cholesterol114 ± 9 (43)123 ± 6 (30)20 ± 9 (44)
    Apolipoprotein B127 ± 5 (25)108 ± 4 (20)*−12 ± 4 (21)*
    HDL cholesterol42 ± 2 (9)52 ± 3 (13)*24 ± 5 (23)*
    Apolipoprotein A-I150 ± 4 (21)164 ± 6 (31)9 ± 3 (14)
    Non-HDL cholesterol177 ± 8 (37)152 ± 6 (31)−12 ± 4 (19)
Vasomotor function
    Brachial artery diameter (mm)
Basal 13.76 ± 0.10 (0.47)3.76 ± 0.07 (0.34)1 ± 2 (9)
Hyperemia3.93 ± 0.10 (0.48)4.00 ± 0.08 (0.37)2 ± 2 (9)
Basal 23.77 ± 0.10 (0.47)3.79 ± 0.08 (0.39)1 ± 2 (10)
Nitroglycerin4.25 ± 0.10 (0.49)4.31 ± 0.09 (0.46)2 ± 2 (9)
    Flow-mediated dilation (%)4.55 ± 0.29 (1.42)6.34 ± 0.29 (1.44)*47 ± 6 (31)*
    Nitroglycerin dilation (%)12.89 ± 0.69 (3.36)13.06 ± 0.63 (3.07)5 ± 5 (24)
    Fibrinogen (mg/dl)288 ± 10 (51)238 ± 11 (56)*−17 ± 3 (16)*
    CRP (mg/l)0.75 (0.50–2.05)0.80 (0.40–1.75)61 ± 64 (314)
Insulin resistance
    ADP (μg/ml)3.35 (2.18–4.67)3.55 (2.51–4.96)12 ± 6 (30)
    Insulin (μU/ml)4.29 ± 0.50 (2.44)3.79 ± 0.71 (3.47)−13 ± 10 (51)
    Glucose (mg/dl)95 ± 7 (32)95 ± 6 (28)2 ± 3 (17)
    QUICKI0.405 ± 0.012 (0.057)0.430 ± 0.015 (0.072)6 ± 3 (13)
  • Data are expressed as means ± SE (SD) or median (25th–75th percentile).

  • *

    * P < 0.001,

  • P < 0.01,

  • P < 0.05 vs. placebo. After testing data for normality, we used Student’s paired t or Wilcoxon signed rank test to compare the relative changes in values in response to placebo and fenofibrate treatments. Non-HDL cholesterol = total cholesterol − HDL cholesterol. QUICKI = 1/[log(insulin) + log(glucose)] (8).